Search for other works by this author on: ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ...

ZW209, a DLL3 targeted trispecific T cell engager with integrated ... and safety following repeat dosing. Session Title: Antibody-Based Cancer Therapeutics 2 ZW327 is a potential first-in-class ...

EyeBio’s main asset is Restoret, an intravitreally delivered trispecific antibody that acts as an agonist of the Wnt signalling pathway and is in the phase 1b/2a AMARONE study in DME and ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...

ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation ... In a non-human primate (NHP) study, ZW209 demonstrated favorable pharmacokinetics (PK) and safety following ...

ZW209, a DLL3 targeted trispecific T cell engager with integrated ... T Cell Engagers and Novel Antibody-Based Therapies ZW209 was designed for optimal T cell binding and enhanced target-dependent ...

ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation ... In a non-human primate (NHP) study, ZW209 demonstrated favorable pharmacokinetics (PK) and safety following ...

ZW209, a DLL3 targeted trispecific T cell engager with integrated ... Zymeworks identified a lead biparatopic antibody displaying improved binding and receptor-mediated internalization relative ...